Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Lutetium-(177Lu)-oxodotreotide

Various toxicities

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Mansour LA, et al. Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177lu-dotatateĠ peptide Receptor Radionuclide Therapy: The MesenLuth Study, et al. National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network. Journal of Nuclear Medicine 65 : 258-263, No. 2, Feb 2024. Available from: URL: https://dx.doi.org/10.2967/jnumed.123.266063 Mansour LA, et al. Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177lu-dotatateĠ peptide Receptor Radionuclide Therapy: The MesenLuth Study, et al. National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network. Journal of Nuclear Medicine 65 : 258-263, No. 2, Feb 2024. Available from: URL: https://​dx.​doi.​org/​10.​2967/​jnumed.​123.​266063
Metadaten
Titel
Lutetium-(177Lu)-oxodotreotide
Various toxicities
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-54539-1

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Antineoplastics

Case report

Multiple drugs